Treatment efficacy
malignant rhaboid tumor
WILMS TUMOR, LYMPH NODE METASTASES, RHABDOMYOSARCOMA
At 3‐year follow‐up, one participant in the push group and six participants in the one‐hour group had an adverse treatment outcome (Table Characteristics of participants with an adverse treatment outcome.Abbreviations: EFS, event‐free survival; HR, high risk; N.A, not applicable; RMS, rhabdomyosarcoma; VHR, very high risk.After initial diagnosis with a Wilms tumor, the participant received a different diagnosis during treatment (malignant rhaboid tumor of the kidney with pulmonary and lymph node metastases) and was subsequently excluded from the study. All vincristine administrations were given as 1‐hour infusion.